文献速递细菌感染、耐药与抗菌药物医院感染防控

个性化随机对照试验设计:定义碳青霉烯耐药感染最优治疗的新范式

Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections.
PubMed 文献 · Lancet Infect Dis · 2021-04-21

本文提出将网络荟萃分析思路延伸至个体随机化的个性化随机对照试验(PRACTical)设计,用于比较多种碳青霉烯耐药感染治疗方案。每例患者仅被随机分配至当时临床上合理的方案,分析可同时利用直接与间接比较,从而识别整体最优或排序最佳的治疗方案。

要点

  • 碳青霉烯耐药感染治疗存在多重临床不确定性,单对照试验难以回答最佳方案问题。
  • PRACTical设计将网络荟萃分析思路用于个体随机化,每例患者仅随机至临床合理方案。
  • 分析可整合直接与间接比较,识别疗效与安全性排序最优的方案。

核心结论

  • 个性化随机对照试验设计可比较多种碳青霉烯耐药感染治疗方案,识别整体最优或相互排序。

研究设计与样本

  • 本文为Personal View,提出将网络荟萃分析思路延伸至个体随机化的PRACTical设计。
  • 该设计针对碳青霉烯耐药肠杆菌目、鲍曼不动杆菌或铜绿假单胞菌感染的治疗方案比较。

主要发现

  • 单对照试验无法回答WHO列为高优先级的公共卫生问题,即现有方案中哪些最能显著降低发病率、费用和死亡率。
  • 碳青霉烯耐药细菌感染治疗试验面临缺乏广泛接受的最优标准治疗与对照方案、抗菌药物敏感性及临床禁忌证各异、诊断与招募困难等障碍。

关键数值与推荐

  • 每例患者仅被随机分配至当时对其临床合理的方案,纳入抗菌药物敏感性、毒性特征、药代动力学属性、可及性和医师评估。
  • 分析可使用跨网络的直接与间接比较,类似网络荟萃分析。
  • 可识别任一某个性化随机化列表中疗效与安全性排序最高的方案。

临床怎么用

  • 对于危及生命的碳青霉烯耐药感染,可考虑采用PRACTical设计开展多方案比较试验。
  • 随机分组时应结合抗菌药物敏感性、毒性、药代动力学、可及性及医师判断为每例患者限定合理方案。

局限性

  • 本文为Personal View,未报告具体试验实施数据或样本量。
  • 原文未报告该设计在真实试验中的可行性验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance is impacting treatment decisions for, and patient outcomes from, bacterial infections worldwide, with particular threats from infections with carbapenem-resistant Enterobacteriaceae, Acinetobacter baumanii, or Pseudomonas aeruginosa. Numerous areas of clinical uncertainty surround the treatment of these highly resistant infections, yet substantial obstacles exist to the design and conduct of treatment trials for carbapenem-resistant bacterial infections. These include the lack of a widely acceptable optimised standard of care and control regimens, varying antimicrobial susceptibilities and clinical contraindications making specific intervention regimens infeasible, and diagnostic and recruitment challenges. The current single comparator trials are not designed to answer the urgent public health question, identified as a high priority by WHO, of what are the best regimens out of the available options that will significantly reduce morbidity, costs, and mortality. This scenario has an analogy in network meta-analysis, which compares multiple treatments in an evidence synthesis to rank the best of a set of available treatments. To address these obstacles, we propose extending the network meta-analysis approach to individual randomisation of patients. We refer to this approach as a Personalised RAndomised Controlled Trial (PRACTical) design that compares multiple treatments in an evidence synthesis, to identify, overall, which is the best treatment out of a set of available treatments to recommend, or how these different treatments rank against each other. In this Personal View, we summarise the design principles of personalised randomised controlled trial designs. Specifically, of a network of different potential regimens for life-threatening carbapenem-resistant infections, each patient would be randomly assigned only to regimens considered clinically reasonable for that patient at that time, incorporating antimicrobial susceptibility, toxicity profile, pharmacometric properties, availability, and physician assessment. Analysis can use both direct and indirect comparisons across the network, analogous to network meta-analysis. This new trial design will maximise the relevance of the findings to each individual patient, and enable the top-ranked regimens from any personalised randomisation list to be identified, in terms of both efficacy and safety.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Walker AS, White IR, Turner RM, et al. Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections. Lancet Infect Dis. 2021. PMID: 33894130. doi:10.1016/S1473-3099(20)30791-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。